Literature DB >> 33562570

Cardiopulmonary and Neurologic Dysfunctions in Fibrodysplasia Ossificans Progressiva.

Fatima Khan1, Xiaobing Yu2, Edward C Hsiao3.   

Abstract

Fibrodysplasia Ossificans Progressiva (FOP) is an ultra-rare but debilitating disorder characterized by spontaneous, progressive, and irreversible heterotopic ossifications (HO) at extraskeletal sites. FOP is caused by gain-of-function mutations in the Activin receptor Ia/Activin-like kinase 2 gene (Acvr1/Alk2), with increased receptor sensitivity to bone morphogenetic proteins (BMPs) and a neoceptor response to Activin A. There is extensive literature on the skeletal phenotypes in FOP, but a much more limited understanding of non-skeletal manifestations of this disease. Emerging evidence reveals important cardiopulmonary and neurologic dysfunctions in FOP including thoracic insufficiency syndrome, pulmonary hypertension, conduction abnormalities, neuropathic pain, and demyelination of the central nervous system (CNS). Here, we review the recent research and discuss unanswered questions regarding the cardiopulmonary and neurologic phenotypes in FOP.

Entities:  

Keywords:  ACVR1; Fibrodysplasia Ossificans Progressiva (FOP); cardiac conduction abnormalities; cardiac dysfunction; neurological dysfunction; neuropathic pain

Year:  2021        PMID: 33562570      PMCID: PMC7915901          DOI: 10.3390/biomedicines9020155

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  141 in total

1.  Multiple roles of bone morphogenetic protein signaling in the regulation of cortical cell number and phenotype.

Authors:  P C Mabie; M F Mehler; J A Kessler
Journal:  J Neurosci       Date:  1999-08-15       Impact factor: 6.167

Review 2.  Multifunctional roles of activins in the brain.

Authors:  Hiroshi Ageta; Kunihiro Tsuchida
Journal:  Vitam Horm       Date:  2011       Impact factor: 3.421

3.  Strong induction of activin expression after hippocampal lesion.

Authors:  Y P Tretter; B Munz; G Hübner; G ten Bruggencate; S Werner; C Alzheimer
Journal:  Neuroreport       Date:  1996-07-29       Impact factor: 1.837

4.  Heterotopic ossification following traumatic and combat-related amputations. Prevalence, risk factors, and preliminary results of excision.

Authors:  Benjamin K Potter; Travis C Burns; Anton P Lacap; Robert R Granville; Donald A Gajewski
Journal:  J Bone Joint Surg Am       Date:  2007-03       Impact factor: 5.284

Review 5.  Immunogenicity of bone morphogenetic proteins.

Authors:  Chang Ju Hwang; Alexander R Vaccaro; James P Lawrence; Joseph Hong; Huub Schellekens; Moulay Hicham Alaoui-Ismaili; Dean Falb
Journal:  J Neurosurg Spine       Date:  2009-05

6.  Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling.

Authors:  Haitao Wang; Carter Lindborg; Vitali Lounev; Jung-Hoon Kim; Ruth McCarrick-Walmsley; Meiqi Xu; Laura Mangiavini; Jay C Groppe; Eileen M Shore; Ernestina Schipani; Frederick S Kaplan; Robert J Pignolo
Journal:  J Bone Miner Res       Date:  2016-04-20       Impact factor: 6.741

Review 7.  Sex, gender, and pain: a review of recent clinical and experimental findings.

Authors:  Roger B Fillingim; Christopher D King; Margarete C Ribeiro-Dasilva; Bridgett Rahim-Williams; Joseph L Riley
Journal:  J Pain       Date:  2009-05       Impact factor: 5.820

8.  Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors.

Authors:  Stuart M Chambers; Yuchen Qi; Yvonne Mica; Gabsang Lee; Xin-Jun Zhang; Lei Niu; James Bilsland; Lishuang Cao; Edward Stevens; Paul Whiting; Song-Hai Shi; Lorenz Studer
Journal:  Nat Biotechnol       Date:  2012-07-01       Impact factor: 54.908

9.  Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling.

Authors:  Stuart M Chambers; Christopher A Fasano; Eirini P Papapetrou; Mark Tomishima; Michel Sadelain; Lorenz Studer
Journal:  Nat Biotechnol       Date:  2009-03-01       Impact factor: 54.908

10.  Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma.

Authors:  Kathryn R Taylor; Alan Mackay; Nathalène Truffaux; Yaron Butterfield; Olena Morozova; Cathy Philippe; David Castel; Catherine S Grasso; Maria Vinci; Diana Carvalho; Angel M Carcaboso; Carmen de Torres; Ofelia Cruz; Jaume Mora; Natacha Entz-Werle; Wendy J Ingram; Michelle Monje; Darren Hargrave; Alex N Bullock; Stéphanie Puget; Stephen Yip; Chris Jones; Jacques Grill
Journal:  Nat Genet       Date:  2014-04-06       Impact factor: 38.330

View more
  4 in total

1.  ALK Inhibitors for Treating Cancer, Blood, and Kidney Diseases.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2022-09-07       Impact factor: 4.632

2.  An ACVR1 activating mutation causes neuropathic pain and sensory neuron hyperexcitability in humans.

Authors:  Xiaobing Yu; Amy N Ton; Zejun Niu; Blanca M Morales; Jiadong Chen; Joao Braz; Michael H Lai; Emilie Barruet; Hongju Liu; Kin Cheung; Syed Ali; Tea Chan; Katherine Bigay; Jennifer Ho; Ina Nikolli; Steven Hansberry; Kelly Wentworth; Arnold Kriegstein; Allan Basbaum; Edward C Hsiao
Journal:  Pain       Date:  2022-04-20       Impact factor: 7.926

Review 3.  BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP).

Authors:  Oscar Will Towler; Eileen M Shore
Journal:  Dev Dyn       Date:  2021-06-26       Impact factor: 2.842

4.  Editorial of Special Issue "Fibrodysplasia Ossificans Progressiva: Studies on Disease Mechanism towards Novel Therapeutic Approaches".

Authors:  Roberto Ravazzolo
Journal:  Biomedicines       Date:  2022-01-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.